(diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes (Mahoney) + (MEF-1) + (Saukett)] + haemophilus influenzae [serotype B]) vaccine

Trials studying (diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes (Mahoney) + (MEF-1) + (Saukett)] + haemophilus influenzae [serotype B]) vaccine

• phase3Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Ageactive not recruitingn=1,714
• phase3Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Ageactive not recruitingn=2,360
• phase3Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Ageactive not recruitingn=580
• phase4Safety, Tolerability, and Immunogenicity of Vaxelis™ in Children Previously Vaccinated With Vaxelis™ or Hexyon™ (V419-016)completedn=168
• phase4Immunogenicity of H. Influenzae Type b PRP-OMP Vaccines in American Indian and Alaska Native Children (the HibVax Study)completedn=333